Linked Life Data

15550857

Source:http://linkedlifedata.com/resource/pubmed/id/15550857

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2004-11-19
pubmed:abstractText
Recently, primary chemotherapy has been used not only for locally advanced breast cancers but also operable cases in an adjuvant setting. Therefore, many randomized clinical trials for primary chemotherapy have been coducted all over the world, with the result that more than one-third of the cases have become nonpalpable (clinical CR). On the contrary, accurate determination of the surgical margin has become more difficult. If some cancer remains as a nonpalpable lesion, it must be detected. Breast MRI has been assuming an important role in the assessment of the extent of cancer and does so more accurately than conventional modalities such as mammography and ultrasonography. Image-guided biopsy or mapping is promising and should be developed as soon as possible. In this article, some promising modalities for the detection of residual lesions after primary chemotherapy are extensively reviewed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:issn
1340-6868
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
134-8
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Present role and future perspectives of the evaluation of the effect of primary chemotherapy by breast imaging.
pubmed:affiliation
Department of Surgery, St.Luke's International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-0044, Japan. seigonak@luke.or.jp
pubmed:publicationType
Journal Article, Review